View ValuationKrka d. d 将来の成長Future 基準チェック /26Krka d. d利益と収益がそれぞれ年間5.8%と5.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.1% 6.7%なると予測されています。主要情報5.8%収益成長率6.69%EPS成長率Pharmaceuticals 収益成長10.5%収益成長率5.5%将来の株主資本利益率18.06%アナリストカバレッジLow最終更新日09 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesUpcoming Dividend • Jul 14Upcoming dividend of €9.10 per shareEligible shareholders must have bought the stock before 21 July 2026. Payment date: 23 July 2026. Payout ratio and cash payout ratio are on the higher end at 76% and 78% respectively. Trailing yield: 3.4%. Lower than top quartile of Polish dividend payers (6.9%). Higher than average of industry peers (2.7%).お知らせ • May 16Krka, d. d., Annual General Meeting, Jul 09, 2026Krka, d. d., Annual General Meeting, Jul 09, 2026, at 13:00 Central European Standard Time.Reported Earnings • May 15First quarter 2026 earnings released: EPS: €3.69 (vs €4.97 in 1Q 2025)First quarter 2026 results: EPS: €3.69 (down from €4.97 in 1Q 2025). Revenue: €565.8m (up 8.4% from 1Q 2025). Net income: €120.9m (down 21% from 1Q 2025). Profit margin: 21% (down from 29% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • Apr 05Dividend of €9.10 announcedShareholders will receive a dividend of €9.10. Ex-date: 21st July 2026 Payment date: 23rd July 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (63% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 12Full year 2025 earnings released: EPS: €13.21 (vs €11.60 in FY 2024)Full year 2025 results: EPS: €13.21 (up from €11.60 in FY 2024). Revenue: €2.04b (up 6.9% from FY 2024). Net income: €403.2m (up 13% from FY 2024). Profit margin: 20% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 29+ 5 more updatesKrka, d. d. to Report Fiscal Year 2025 Final Results on Mar 12, 2026Krka, d. d. announced that they will report fiscal year 2025 final results at 8:15 AM, Central European Standard Time on Mar 12, 2026Upcoming Dividend • Jul 15Upcoming dividend of €8.25 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 24 July 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Polish dividend payers (7.2%). Higher than average of industry peers (2.8%).Buy Or Sell Opportunity • Jul 09Now 20% undervaluedOver the last 90 days, the stock has risen 15% to zł834. The fair value is estimated to be zł1,048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 2.7% per annum over the same time period.Declared Dividend • May 18Dividend of €8.25 announcedShareholders will receive a dividend of €8.25. Ex-date: 22nd July 2025 Payment date: 24th July 2025 Dividend yield will be 1.1%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 10% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 16Krka, d. d., Annual General Meeting, Jul 10, 2025Krka, d. d., Annual General Meeting, Jul 10, 2025.Reported Earnings • May 15First quarter 2025 earnings released: EPS: €4.97 (vs €3.21 in 1Q 2024)First quarter 2025 results: EPS: €4.97 (up from €3.21 in 1Q 2024). Revenue: €522.1m (up 7.4% from 1Q 2024). Net income: €152.2m (up 54% from 1Q 2024). Profit margin: 29% (up from 20% in 1Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Approved (during full year): 18 Launched (during full year): 10 Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 29+ 4 more updatesKrka, d. d. to Report Fiscal Year 2024 Results on Jan 30, 2025Krka, d. d. announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Jan 30, 2025Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: €1.93 (vs €2.11 in 3Q 2023)Third quarter 2024 results: EPS: €1.93 (down from €2.11 in 3Q 2023). Revenue: €449.2m (up 6.9% from 3Q 2023). Net income: €59.2m (down 9.3% from 3Q 2023). Profit margin: 13% (down from 16% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year.Buy Or Sell Opportunity • Jul 25Now 20% undervaluedOver the last 90 days, the stock has risen 9.9% to zł600. The fair value is estimated to be zł751, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings are also forecast to grow by 4.6% per annum over the same time period.Reported Earnings • Jul 19Second quarter 2024 earnings released: EPS: €3.99 (vs €2.62 in 2Q 2023)Second quarter 2024 results: EPS: €3.99 (up from €2.62 in 2Q 2023). Revenue: €499.3m (up 8.0% from 2Q 2023). Net income: €123.0m (up 52% from 2Q 2023). Profit margin: 25% (up from 18% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jul 16Upcoming dividend of €7.50 per shareEligible shareholders must have bought the stock before 23 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 5.1%. Lower than top quartile of Polish dividend payers (7.3%). Higher than average of industry peers (2.2%).Buy Or Sell Opportunity • Jun 05Now 21% undervaluedOver the last 90 days, the stock has risen 4.5% to zł560. The fair value is estimated to be zł707, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period.Declared Dividend • May 19Dividend of €7.50 announcedShareholders will receive a dividend of €7.50. Ex-date: 23rd July 2024 Payment date: 25th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (69% earnings payout ratio) but not covered by cash flows (166% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 17First quarter 2024 earnings released: EPS: €3.21 (vs €2.87 in 1Q 2023)First quarter 2024 results: EPS: €3.21 (up from €2.87 in 1Q 2023). Revenue: €486.1m (up 6.1% from 1Q 2023). Net income: €98.9m (up 11% from 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Apr 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 10 Launched (during full year): 8 Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Mar 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.お知らせ • Dec 01+ 6 more updatesKrka, d. d. to Report Q1, 2024 Results on May 16, 2024Krka, d. d. announced that they will report Q1, 2024 results at 8:15 AM, Central European Standard Time on May 16, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: €2.11 (vs €2.10 in 3Q 2022)Third quarter 2023 results: EPS: €2.11 (up from €2.10 in 3Q 2022). Revenue: €420.1m (up 9.2% from 3Q 2022). Net income: €65.3m (flat on 3Q 2022). Profit margin: 16% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year.Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: €2.62 (vs €4.67 in 2Q 2022)Second quarter 2023 results: EPS: €2.62 (down from €4.67 in 2Q 2022). Revenue: €462.2m (up 8.8% from 2Q 2022). Net income: €80.9m (down 44% from 2Q 2022). Profit margin: 18% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year.Buying Opportunity • Jul 20Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.3%. The fair value is estimated to be zł637, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 2.6% per annum over the same time period.Upcoming Dividend • Jul 11Upcoming dividend of €6.60 per share at 5.7% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 20 July 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (7.1%). Higher than average of industry peers (2.7%).Buying Opportunity • May 24Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be zł633, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 4.6% per annum over the same time period.Reported Earnings • May 18First quarter 2023 earnings released: EPS: €2.87 (vs €2.91 in 1Q 2022)First quarter 2023 results: EPS: €2.87 (down from €2.91 in 1Q 2022). Revenue: €458.2m (up 5.9% from 1Q 2022). Net income: €89.0m (down 1.5% from 1Q 2022). Profit margin: 19% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.Reported Earnings • Mar 17Full year 2022 earnings released: EPS: €11.69 (vs €9.92 in FY 2021)Full year 2022 results: EPS: €11.69 (up from €9.92 in FY 2021). Revenue: €1.72b (up 9.7% from FY 2021). Net income: €363.3m (up 18% from FY 2021). Profit margin: 21% (up from 20% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 31Krka Reportedly Eyes Promoter Stake in Unichem LaboratoriesKrka, d. d. (LJSE:KRKG) is in discussions to acquire the promoter’s stake in Mumbai-based Unichem Laboratories Limited (BSE:506690), said two people aware of the development. Promoter Prakash Amrut Mody & family owns a 50.93% stake in the listed entity. An acquisition of this stake will trigger an open offer for an additional 26% of equity.お知らせ • Dec 01+ 6 more updatesKrka, d. d., Annual General Meeting, Jul 06, 2023Krka, d. d., Annual General Meeting, Jul 06, 2023, at 01:00 Central European Standard Time.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €2.10 (vs €2.02 in 3Q 2021)Third quarter 2022 results: EPS: €2.10 (up from €2.02 in 3Q 2021). Revenue: €384.8m (up 4.6% from 3Q 2021). Net income: €65.3m (up 4.1% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year.Reported Earnings • Jul 22Second quarter 2022 earnings released: EPS: €4.67 (vs €2.93 in 2Q 2021)Second quarter 2022 results: EPS: €4.67 (up from €2.93 in 2Q 2021). Revenue: €425.0m (up 3.0% from 2Q 2021). Net income: €145.3m (up 59% from 2Q 2021). Profit margin: 34% (up from 22% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.Upcoming Dividend • Jul 12Upcoming dividend of €5.63 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 21 July 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (8.4%). Higher than average of industry peers (2.6%).Reported Earnings • May 20First quarter 2022 earnings released: EPS: €2.91 (vs €2.77 in 1Q 2021)First quarter 2022 results: EPS: €2.91 (up from €2.77 in 1Q 2021). Revenue: €432.5m (up 9.3% from 1Q 2021). Net income: €90.4m (up 4.5% from 1Q 2021). Profit margin: 21% (down from 22% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 5.5% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 17% per year.Reported Earnings • Mar 19Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €9.92 (up from €9.27 in FY 2020). Revenue: €1.57b (up 2.0% from FY 2020). Net income: €309.2m (up 6.3% from FY 2020). Profit margin: 20% (in line with FY 2020). Post-clinical trial products Approved (during full year): 14 Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 2.5%, compared to a 7.4% growth forecast for the pharmaceuticals industry in Poland. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to zł430, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 95% over the past three years.Reported Earnings • Nov 19Third quarter 2021 earnings released: EPS €2.02 (vs €1.61 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €368.0m (up 3.2% from 3Q 2020). Net income: €62.7m (up 25% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 30Second quarter 2021 earnings released: EPS €2.93 (vs €2.40 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €412.8m (up 21% from 2Q 2020). Net income: €91.5m (up 21% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year.Upcoming Dividend • Jul 13Upcoming dividend of €5.00 per shareEligible shareholders must have bought the stock before 20 July 2021. Payment date: 22 July 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.8%). Higher than average of industry peers (2.7%).Reported Earnings • May 22First quarter 2021 earnings released: EPS €2.77 (vs €2.72 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €395.8m (down 14% from 1Q 2020). Net income: €86.5m (up 1.0% from 1Q 2020). Profit margin: 22% (up from 19% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.Reported Earnings • Apr 17Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Post-clinical trial products Approved (during full year): 20 Launched (during full year): 29 Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.Reported Earnings • Mar 19Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 22% per year.Is New 90 Day High Low • Dec 23New 90-day high: zł420The company is up 9.0% from its price of zł385 on 24 September 2020. The Polish market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł475 per share.Is New 90 Day High Low • Dec 03New 90-day high: zł399The company is up 4.0% from its price of zł383 on 04 September 2020. The Polish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł390 per share.お知らせ • Nov 27+ 6 more updatesKrka, d. d. to Report Q1, 2021 Results on May 20, 2021Krka, d. d. announced that they will report Q1, 2021 results at 8:15 AM, Central European Standard Time on May 20, 2021Reported Earnings • Nov 20Third quarter 2020 earnings released: EPS €1.61The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €356.4m (up 8.2% from 3Q 2019). Net income: €50.4m (up 55% from 3Q 2019). Profit margin: 14% (up from 9.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.業績と収益の成長予測WSE:KRK - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,440462391503412/31/20272,299442359499512/31/20262,16642034045453/31/20262,085372353452N/A12/31/20252,041403430529N/A9/30/20252,009399341440N/A6/30/20251,973381310412N/A3/31/20251,946410359471N/A12/31/20241,910357246361N/A9/30/20241,901360201345N/A6/30/20241,871366175317N/A3/31/20241,834324122263N/A12/31/20231,80631488227N/A9/30/20231,816298204307N/A6/30/20231,780298274377N/A3/31/20231,743362307411N/A12/31/20221,717363373468N/A9/30/20221,631369362458N/A6/30/20221,615367331417N/A3/31/20221,602313288362N/A12/31/20211,566309314386N/A9/30/20211,551320271343N/A6/30/20211,540308253326N/A3/31/20211,468292308379N/A12/31/20201,535291280361N/A9/30/20201,563284273365N/A6/30/20201,536267275380N/A3/31/20201,578261233346N/A12/31/20191,493246N/A350N/A9/30/20191,451226N/A347N/A6/30/20191,414213N/A337N/A3/31/20191,372196N/A306N/A12/31/20181,332175N/A290N/A9/30/20181,310163N/A271N/A6/30/20181,291163N/A241N/A3/31/20181,283159N/A272N/A12/31/20171,266153N/A228N/A9/30/20171,250138N/A206N/A6/30/20171,226130N/A219N/A3/31/20171,195111N/A190N/A12/31/20161,174108N/A213N/A9/30/20161,154105N/A262N/A6/30/20161,169116N/A250N/A3/31/20161,176143N/A304N/A12/31/20151,165158N/A278N/A9/30/20151,197172N/A215N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KRKの予測収益成長率 (年間5.8% ) は 貯蓄率 ( 5.3% ) を上回っています。収益対市場: KRKの収益 ( 5.8% ) Polish市場 ( 12.8% ) よりも低い成長が予測されています。高成長収益: KRKの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: KRKの収益 ( 5.5% ) Polish市場 ( 4.6% ) よりも速いペースで成長すると予測されています。高い収益成長: KRKの収益 ( 5.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KRKの 自己資本利益率 は、3年後には低くなると予測されています ( 18.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/21 01:34終値2026/07/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Krka, d. d. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Simon MatherBarclaysStephane SumarBNP ParibasJamie ClarkBofA Global Research6 その他のアナリストを表示
Upcoming Dividend • Jul 14Upcoming dividend of €9.10 per shareEligible shareholders must have bought the stock before 21 July 2026. Payment date: 23 July 2026. Payout ratio and cash payout ratio are on the higher end at 76% and 78% respectively. Trailing yield: 3.4%. Lower than top quartile of Polish dividend payers (6.9%). Higher than average of industry peers (2.7%).
お知らせ • May 16Krka, d. d., Annual General Meeting, Jul 09, 2026Krka, d. d., Annual General Meeting, Jul 09, 2026, at 13:00 Central European Standard Time.
Reported Earnings • May 15First quarter 2026 earnings released: EPS: €3.69 (vs €4.97 in 1Q 2025)First quarter 2026 results: EPS: €3.69 (down from €4.97 in 1Q 2025). Revenue: €565.8m (up 8.4% from 1Q 2025). Net income: €120.9m (down 21% from 1Q 2025). Profit margin: 21% (down from 29% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • Apr 05Dividend of €9.10 announcedShareholders will receive a dividend of €9.10. Ex-date: 21st July 2026 Payment date: 23rd July 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (63% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: €13.21 (vs €11.60 in FY 2024)Full year 2025 results: EPS: €13.21 (up from €11.60 in FY 2024). Revenue: €2.04b (up 6.9% from FY 2024). Net income: €403.2m (up 13% from FY 2024). Profit margin: 20% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 29+ 5 more updatesKrka, d. d. to Report Fiscal Year 2025 Final Results on Mar 12, 2026Krka, d. d. announced that they will report fiscal year 2025 final results at 8:15 AM, Central European Standard Time on Mar 12, 2026
Upcoming Dividend • Jul 15Upcoming dividend of €8.25 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 24 July 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Polish dividend payers (7.2%). Higher than average of industry peers (2.8%).
Buy Or Sell Opportunity • Jul 09Now 20% undervaluedOver the last 90 days, the stock has risen 15% to zł834. The fair value is estimated to be zł1,048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 2.7% per annum over the same time period.
Declared Dividend • May 18Dividend of €8.25 announcedShareholders will receive a dividend of €8.25. Ex-date: 22nd July 2025 Payment date: 24th July 2025 Dividend yield will be 1.1%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 10% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 16Krka, d. d., Annual General Meeting, Jul 10, 2025Krka, d. d., Annual General Meeting, Jul 10, 2025.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: €4.97 (vs €3.21 in 1Q 2024)First quarter 2025 results: EPS: €4.97 (up from €3.21 in 1Q 2024). Revenue: €522.1m (up 7.4% from 1Q 2024). Net income: €152.2m (up 54% from 1Q 2024). Profit margin: 29% (up from 20% in 1Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Approved (during full year): 18 Launched (during full year): 10 Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 29+ 4 more updatesKrka, d. d. to Report Fiscal Year 2024 Results on Jan 30, 2025Krka, d. d. announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Jan 30, 2025
Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: €1.93 (vs €2.11 in 3Q 2023)Third quarter 2024 results: EPS: €1.93 (down from €2.11 in 3Q 2023). Revenue: €449.2m (up 6.9% from 3Q 2023). Net income: €59.2m (down 9.3% from 3Q 2023). Profit margin: 13% (down from 16% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year.
Buy Or Sell Opportunity • Jul 25Now 20% undervaluedOver the last 90 days, the stock has risen 9.9% to zł600. The fair value is estimated to be zł751, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings are also forecast to grow by 4.6% per annum over the same time period.
Reported Earnings • Jul 19Second quarter 2024 earnings released: EPS: €3.99 (vs €2.62 in 2Q 2023)Second quarter 2024 results: EPS: €3.99 (up from €2.62 in 2Q 2023). Revenue: €499.3m (up 8.0% from 2Q 2023). Net income: €123.0m (up 52% from 2Q 2023). Profit margin: 25% (up from 18% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jul 16Upcoming dividend of €7.50 per shareEligible shareholders must have bought the stock before 23 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 5.1%. Lower than top quartile of Polish dividend payers (7.3%). Higher than average of industry peers (2.2%).
Buy Or Sell Opportunity • Jun 05Now 21% undervaluedOver the last 90 days, the stock has risen 4.5% to zł560. The fair value is estimated to be zł707, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period.
Declared Dividend • May 19Dividend of €7.50 announcedShareholders will receive a dividend of €7.50. Ex-date: 23rd July 2024 Payment date: 25th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (69% earnings payout ratio) but not covered by cash flows (166% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 17First quarter 2024 earnings released: EPS: €3.21 (vs €2.87 in 1Q 2023)First quarter 2024 results: EPS: €3.21 (up from €2.87 in 1Q 2023). Revenue: €486.1m (up 6.1% from 1Q 2023). Net income: €98.9m (up 11% from 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Apr 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 10 Launched (during full year): 8 Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Mar 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.
お知らせ • Dec 01+ 6 more updatesKrka, d. d. to Report Q1, 2024 Results on May 16, 2024Krka, d. d. announced that they will report Q1, 2024 results at 8:15 AM, Central European Standard Time on May 16, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: €2.11 (vs €2.10 in 3Q 2022)Third quarter 2023 results: EPS: €2.11 (up from €2.10 in 3Q 2022). Revenue: €420.1m (up 9.2% from 3Q 2022). Net income: €65.3m (flat on 3Q 2022). Profit margin: 16% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year.
Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: €2.62 (vs €4.67 in 2Q 2022)Second quarter 2023 results: EPS: €2.62 (down from €4.67 in 2Q 2022). Revenue: €462.2m (up 8.8% from 2Q 2022). Net income: €80.9m (down 44% from 2Q 2022). Profit margin: 18% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year.
Buying Opportunity • Jul 20Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.3%. The fair value is estimated to be zł637, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 2.6% per annum over the same time period.
Upcoming Dividend • Jul 11Upcoming dividend of €6.60 per share at 5.7% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 20 July 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (7.1%). Higher than average of industry peers (2.7%).
Buying Opportunity • May 24Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be zł633, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 4.6% per annum over the same time period.
Reported Earnings • May 18First quarter 2023 earnings released: EPS: €2.87 (vs €2.91 in 1Q 2022)First quarter 2023 results: EPS: €2.87 (down from €2.91 in 1Q 2022). Revenue: €458.2m (up 5.9% from 1Q 2022). Net income: €89.0m (down 1.5% from 1Q 2022). Profit margin: 19% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.
Reported Earnings • Mar 17Full year 2022 earnings released: EPS: €11.69 (vs €9.92 in FY 2021)Full year 2022 results: EPS: €11.69 (up from €9.92 in FY 2021). Revenue: €1.72b (up 9.7% from FY 2021). Net income: €363.3m (up 18% from FY 2021). Profit margin: 21% (up from 20% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 31Krka Reportedly Eyes Promoter Stake in Unichem LaboratoriesKrka, d. d. (LJSE:KRKG) is in discussions to acquire the promoter’s stake in Mumbai-based Unichem Laboratories Limited (BSE:506690), said two people aware of the development. Promoter Prakash Amrut Mody & family owns a 50.93% stake in the listed entity. An acquisition of this stake will trigger an open offer for an additional 26% of equity.
お知らせ • Dec 01+ 6 more updatesKrka, d. d., Annual General Meeting, Jul 06, 2023Krka, d. d., Annual General Meeting, Jul 06, 2023, at 01:00 Central European Standard Time.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €2.10 (vs €2.02 in 3Q 2021)Third quarter 2022 results: EPS: €2.10 (up from €2.02 in 3Q 2021). Revenue: €384.8m (up 4.6% from 3Q 2021). Net income: €65.3m (up 4.1% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year.
Reported Earnings • Jul 22Second quarter 2022 earnings released: EPS: €4.67 (vs €2.93 in 2Q 2021)Second quarter 2022 results: EPS: €4.67 (up from €2.93 in 2Q 2021). Revenue: €425.0m (up 3.0% from 2Q 2021). Net income: €145.3m (up 59% from 2Q 2021). Profit margin: 34% (up from 22% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.
Upcoming Dividend • Jul 12Upcoming dividend of €5.63 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 21 July 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (8.4%). Higher than average of industry peers (2.6%).
Reported Earnings • May 20First quarter 2022 earnings released: EPS: €2.91 (vs €2.77 in 1Q 2021)First quarter 2022 results: EPS: €2.91 (up from €2.77 in 1Q 2021). Revenue: €432.5m (up 9.3% from 1Q 2021). Net income: €90.4m (up 4.5% from 1Q 2021). Profit margin: 21% (down from 22% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 5.5% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 17% per year.
Reported Earnings • Mar 19Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €9.92 (up from €9.27 in FY 2020). Revenue: €1.57b (up 2.0% from FY 2020). Net income: €309.2m (up 6.3% from FY 2020). Profit margin: 20% (in line with FY 2020). Post-clinical trial products Approved (during full year): 14 Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 2.5%, compared to a 7.4% growth forecast for the pharmaceuticals industry in Poland. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to zł430, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 95% over the past three years.
Reported Earnings • Nov 19Third quarter 2021 earnings released: EPS €2.02 (vs €1.61 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €368.0m (up 3.2% from 3Q 2020). Net income: €62.7m (up 25% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 30Second quarter 2021 earnings released: EPS €2.93 (vs €2.40 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €412.8m (up 21% from 2Q 2020). Net income: €91.5m (up 21% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year.
Upcoming Dividend • Jul 13Upcoming dividend of €5.00 per shareEligible shareholders must have bought the stock before 20 July 2021. Payment date: 22 July 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.8%). Higher than average of industry peers (2.7%).
Reported Earnings • May 22First quarter 2021 earnings released: EPS €2.77 (vs €2.72 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €395.8m (down 14% from 1Q 2020). Net income: €86.5m (up 1.0% from 1Q 2020). Profit margin: 22% (up from 19% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Post-clinical trial products Approved (during full year): 20 Launched (during full year): 29 Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.
Reported Earnings • Mar 19Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 22% per year.
Is New 90 Day High Low • Dec 23New 90-day high: zł420The company is up 9.0% from its price of zł385 on 24 September 2020. The Polish market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł475 per share.
Is New 90 Day High Low • Dec 03New 90-day high: zł399The company is up 4.0% from its price of zł383 on 04 September 2020. The Polish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł390 per share.
お知らせ • Nov 27+ 6 more updatesKrka, d. d. to Report Q1, 2021 Results on May 20, 2021Krka, d. d. announced that they will report Q1, 2021 results at 8:15 AM, Central European Standard Time on May 20, 2021
Reported Earnings • Nov 20Third quarter 2020 earnings released: EPS €1.61The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €356.4m (up 8.2% from 3Q 2019). Net income: €50.4m (up 55% from 3Q 2019). Profit margin: 14% (up from 9.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.